Results for
"[search-keyword]"
Sponsor content
25 result(s) found, displaying 1 to 10
- VaxchoraPrescription medicine decision summaryVaxchora (vibrio cholerae) is approved to prevent disease caused by Vibrio cholerae serogroup O1 in those travelling to cholera-affected countries.
- Vaxchora Vibrio cholerae bacteria cells (CVD 103-HgR strain) 4 x 10^8 to 2 x 10^9 CFU suspension, powder for, sachet (389746)ARTGAustralian Register of Therapeutic Goods (ARTG) information for Vaxchora Vibrio cholerae bacteria cells (CVD 103-HgR strain) 4 x 10^8 to 2 x 10^9 CFU suspension, powder for, sachet.
- AusPAR: NuvaxovidAustralian Public Assessment Report (AusPAR)Nuvaxovid (SARS-CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for prevention of COVID-19 in individuals 12 years of age and older.
- NUVAXOVID-SARS-CoV-2 rS (NVX-CoV2373) (Biocelect Pty Ltd)Prescription medicine registrationActive ingredients: SARS-CoV-2 rS (NVX-CoV2373).
- STANDARD™ Q COVID-19 Ag Test Nasal SwabCOVID-19 test kitAntigen Test - Intended for use: Point-of-care
- VAXCHORA Biocelect Pty LtdJul-2022Prescription medicine evaluationActive ingredient: Vibrio cholerae.
- AusPAR: Nuvaxovid homologous boosterAustralian Public Assessment Report (AusPAR)Nuvaxovid homologous booster (CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for the prevention of COVID-19.
- AusPAR: Nuvaxovid heterologous boosterAustralian Public Assessment Report (AusPAR)Nuvaxovid heterologous booster (CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for the prevention of COVID-19.
- AusPAR: SARS-CoV-2 rS with Matrix-M adjuvantAustralian Public Assessment Report (AusPAR)Australian Public Assessment Report for SARS-CoV-2 rS with Matrix-M adjuvant